453 related articles for article (PubMed ID: 34063568)
1. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
2. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R
Mol Cell Proteomics; 2019 Sep; 18(9):1836-1850. PubMed ID: 31289117
[TBL] [Abstract][Full Text] [Related]
3. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
Jordan HA; Thomas SN
Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719
[TBL] [Abstract][Full Text] [Related]
4. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
Zhang W; Peng P; Ou X; Shen K; Wu X
BMC Cancer; 2019 Nov; 19(1):1095. PubMed ID: 31718609
[TBL] [Abstract][Full Text] [Related]
6. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
7. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.
Pitteri SJ; JeBailey L; Faça VM; Thorpe JD; Silva MA; Ireton RC; Horton MB; Wang H; Pruitt LC; Zhang Q; Cheng KH; Urban N; Hanash SM; Dinulescu DM
PLoS One; 2009 Nov; 4(11):e7916. PubMed ID: 19936259
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling in ovarian cancer.
Kim G; Minig L; Kohn EC
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis for early detection of ovarian cancer: a realistic approach?
Stevens EV; Liotta LA; Kohn EC
Int J Gynecol Cancer; 2003; 13 Suppl 2():133-9. PubMed ID: 14656269
[TBL] [Abstract][Full Text] [Related]
10. MASS SPECTROMETRY-BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS.
Li N; Zhan X
Mass Spectrom Rev; 2020 Sep; 39(5-6):471-498. PubMed ID: 32020673
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.
Swiatly A; Plewa S; Matysiak J; Kokot ZJ
J Ovarian Res; 2018 Oct; 11(1):88. PubMed ID: 30270814
[TBL] [Abstract][Full Text] [Related]
13. [Molecular diagnostics of ovarian cancer using proteome techniques].
Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
[TBL] [Abstract][Full Text] [Related]
14. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.
Wei BR; Hoover SB; Ross MM; Zhou W; Meani F; Edwards JB; Spehalski EI; Risinger JI; Alvord WG; Quiñones OA; Belluco C; Martella L; Campagnutta E; Ravaggi A; Dai RM; Goldsmith PK; Woolard KD; Pecorelli S; Liotta LA; Petricoin EF; Simpson RM
PLoS One; 2009 Oct; 4(10):e7670. PubMed ID: 19888321
[TBL] [Abstract][Full Text] [Related]
15. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.
Huang R; Chen Z; He L; He N; Xi Z; Li Z; Deng Y; Zeng X
Theranostics; 2017; 7(14):3559-3572. PubMed ID: 28912895
[TBL] [Abstract][Full Text] [Related]
17. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
18. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
19. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
20. Proteomics as a guiding tool for more effective personalized therapy.
Lee JM; Kohn EC
Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]